[FHIR Binary Resource]: http://hl7.org/fhir/binary.html
[FHIR Bulk Data Access (Flat FHIR)]: http://hl7.org/fhir/uv/bulkdata/index.html
[FHIR Communications]: {{site.data.fhir.path}}security.html#http
[FHIR Communications Security]: {{site.data.fhir.path}}security.html#http
[FHIR Conformance Rules]: {{site.data.fhir.path}}conformance-rules.html
[FHIR Data Types]: {{site.data.fhir.path}}datatypes.html
[FHIR Digital Signatures]: {{site.data.fhir.path}}security.html#digital%20signatures
[FHIR Documents]: {{site.data.fhir.path}}documents.html
[FHIR Must Support]: {{site.data.fhir.path}}profiling.html#mustsupport
[FHIR Paging]: {{site.data.fhir.path}}http.html#paging
[FHIR Provenance]: {{site.data.fhir.path}}provenance.html
[FHIR RESTful API]: {{site.data.fhir.path}}http.html
[FHIR RESTful Search API]: {{site.data.fhir.path}}http.html#search
[FHIR RESTful operations]: {{site.data.fhir.path}}operations.html
[FHIR Resource]: {{site.data.fhir.path}}resource.html
[FHIR Search]: {{site.data.fhir.path}}search.html
[FHIR Security Labels]: {{site.data.fhir.path}}security-labels.html
[FHIR Terminology]: {{site.data.fhir.path}}terminologies.html
[FHIR Version 4.0.1]: {{site.data.fhir.path}}index.html "FHIR Specification Home Page"
[FHIR Version DSTU2]: http://hl7.org/fhir/DSTU2/index.html "FHIR Version DSTU2 Specification Home Page"
[FHIR Version R4]: {{site.data.fhir.path}}index.html "FHIR Version R4 Specification Home Page"
[FHIR Version STU3]: http://hl7.org/fhir/STU3/index.html "FHIR Version STU3 Specification Home Page"

[HL7 Fast Healthcare Interoperability Resources&#174; (FHIR&#174;)]: http://hl7.org/fhir
[Medical College of Wisconsin (MCW)]: https://www.mcw.edu
[Center for International Blood &amp; Marrow Transplant Research速 (CIBMTR速)]: https://www.cibmtr.org
[National Marrow Donor Program速 (NMDP)/Be The Match速]: https://bethematch.org
[NMDP/Be The Match]: https://bethematch.org
[Direct FHIR for STU3 Guide]: CIBMTR_Direct_FHIR_API_Connection_Guide_STU3.pdf
[A Growable Network Information System (AGNIS)]: https://www.cibmtr.org/DataManagement/SystemApplications/AGNIS/Pages/default.aspx
[AGNIS]: https://www.cibmtr.org/DataManagement/SystemApplications/AGNIS/Pages/default.aspx
[FormsNet3]: https://www.cibmtr.org/DataManagement/SystemApplications/FormsNet3
[CIBMTR Form 2400 (Pre-TED)]: https://www.cibmtr.org/manuals/fim/1/en/topic/2400 

[US Core FHIR IG]: https://www.hl7.org/fhir/us/core/
[minimal Common Oncology Data Elements (mCODE) IG]: https://hl7.org/fhir/us/mcode/
[mCODE]: https://hl7.org/fhir/us/mcode/

[Connecting and Access]: Connection-Guide-R4.html
[API Endpoints]: Endpoints.html
[Access Credentials]: Access-Credentials.html
[CRID Assignment]: CRID-Assignment.html
[Laboratory Observations]: Laboratory-Observations.html
[Medications]: Medications.html
[Vital Signs]: Vital-Signs.html
[Bundles]: Bundles.html
[Example code]: Example-Code.html
[CIBMTR Patient]: StructureDefinition-cibmtr-patient.html
[Laboratory Observation Results]: StructureDefinition-cibmtr-observation-lab.html
[Laboratory Observation for Priority Variables]: StructureDefinition-cibmtr-obs-priority-variables.html 
[MedicationRequest]: StructureDefinition-cibmtr-medication-request.html
[Medication]: StructureDefinition-cibmtr-medication.html
[CIBMTR Vital Signs]: StructureDefinition-cibmtr-vital-signs.html
[CIBMTR Vital Signs-Height]: StructureDefinition-cibmtr-vital-signs-height.html
[CIBMTR Vital Signs-Weight]: StructureDefinition-cibmtr-vital-signs-weight.html
[Mobilizing Agent Medication]: StructureDefinition-cibmtr-mobilizing-agent-medication.html
[Preprative Regimen Medications]: StructureDefinition-cibmtr-prep-regimen-medication.html
[Additional Drugs in Peri-Transplant Period]: StructureDefinition-cibmtr-additional-peri-transplant-medication.html
[GVHD Prophylaxis Medication]: StructureDefinition-cibmtr-gvhd-prophylaxis-medication.html
[Planned Post-HCT Disease Therapy Medication]: StructureDefinition-cibmtr-post-hct-disease-therapy-planned-medication.html
[Prior Exposure Medication]: StructureDefinition-cibmtr-prior-exposure-medication.html
[CIBMTR Priority Variables for FY22]: ValueSet-cibmtr-priority-variables-2022.html
[LOINC Codes used in Vital Signs]: ValueSet-vital-signs.html
[Mobilizing Agents (auto only)]: ValueSet-med-mobilizing-agents-vs.html
[Prep Regimen]: ValueSet-med-prep-regimen-vs.html
[Additional Drugs in Peri-Transplant Period]: ValueSet-med-addition-peri-transplant-vs.html
[GVHD Prophylaxis]: ValueSet-med-gvhd-prophylaxis-vs.html
[Post-HCT Disease Therapy Planned]: ValueSet-med-post-hct-disease-therapy-planned-vs.html
[Prior Exposure: Potential Study Eligibility]: ValueSet-med-prior-exposure-vs.html
[All Form 2400 Medications]: ValueSet-med-all-form2400-vs.html
[US-Core Laboratory Observation]: https://hl7.org/fhir/us/core/StructureDefinition-us-core-observation-lab.html
[US-Core Laboratory Vital Signs]: https://hl7.org/fhir/us/core/StructureDefinition-us-core-vital-signs.html
[FHIR core specification vital signs table]: https://hl7.org/fhir/R4/observation-vitalsigns.html#vitals-table.html

[Medication-Cyclophosphamide-Example]: Medication-Medication-Cyclophosphamide-Example.html
[Medication-Etoposide-Example]: Medication-Medication-Etoposide-Example.html
[Medication-GVHD-Prophylaxis-Example]:Medication-Medication-GVHD-Prophylaxis-Example.html
[Medication-Mobilizing-Agent-Example]: Medication-Medication-Mobilizing-Agent-Example.html
[Medication-Peri-Transplant-Example]: Medication-Medication-Peri-Transplant-Example.html
[Medication-Post-HCT-Disease-Therapy-Example]: Medication-Medication-Post-HCT-Disease-Therapy-Example.html
[Medication-Prep-Regimen-Example]: Medication-Medication-Prep-Regimen-Example.html
[Medication-PriorExposure-Example]: Medication-Medication-PriorExposure-Example.html
[MedicationAdministration-Example1]: MedicationAdministration-MedicationAdministration-Example1.html
[MedicationAdministration-Example2]: MedicationAdministration-MedicationAdministration-Example2.html
[MedicationRequest-Etoposide-Example]: MedicationRequest-MedicationRequest-Etoposide-Example.html
[Vital Signs Example-Height Measurement Prep Regimen]: Observation-HeightMeasurementPrepRegimen.html

[Form 2450 manual]: https://www.cibmtr.org/manuals/fim/1/en/topic/2450
[Survival]: https://www.cibmtr.org/manuals/fim/1/en/topic/q1-7-100-day-report-only
[Subsequent Transplant]: https://www.cibmtr.org/manuals/fim/1/en/topic/q7-13-subsequent-transplant
[Initial ANC Recovery]: https://www.cibmtr.org/manuals/fim/1/en/topic/q8-11-initial-anc-recovery
[Initial Platelet Recovery]: https://www.cibmtr.org/manuals/fim/1/en/topic/q12-14-initial-platelet-recovery
[Graft versus Host Disease (Allogeneic Only)]: https://www.cibmtr.org/manuals/fim/1/en/topic/q15-18-graft-versus-host-disease-allogeneic-only
[Liver Toxicity Prophylaxis]: https://www.cibmtr.org/manuals/fim/1/en/topic/q39-45-liver-toxicity-prophylaxis
[Veno-occlusive disease (VOD) / Sinusoidal obstruction syndrome (SOS)]: https://www.cibmtr.org/manuals/fim/1/en/topic/q46-47-veno-occlusive-disease-vod-sinusoidal-obstruction-syndrome-sos
[Infection]: https://www.cibmtr.org/manuals/fim/1/en/topic/q50-51-infection
[New Malignancy, Lymphoproliferative or Myeloproliferative Disorder]: https://www.cibmtr.org/manuals/fim/1/en/topic/q19-61-new-malignancy-lymphoproliferative-or-myeloproliferative-disorder
[Chimerism Studies (Cord Blood Units, Beta Thalassemia, and Sickle Cell Disease Only)]: https://www.cibmtr.org/manuals/fim/1/en/topic/q89-107-chimerism-studies-cord-blood-units-only
[Disease Assessment at the Time of Best Response to Infusion]: https://www.cibmtr.org/manuals/fim/1/en/topic/q75-97-disease-assessment
[Post-Infusion Therapy]: https://www.cibmtr.org/manuals/fim/1/en/topic/q75-77-post-hct-therapy
[Relapse or Progression Post-Infusion]: https://www.cibmtr.org/manuals/fim/1/en/topic/q161-234-relapse-or-progression
[Current Disease Status]: https://www.cibmtr.org/manuals/fim/1/en/topic/q235-238-current-disease-status


[Cytogenetics Observation]: StructureDefinition-cibmtr-cytogenetics.html
[Cytogenetics Example]: Observation-Cytogenetics-Example-1.html